UNSPSC 51162739: Stepronin

This classification denotes a mucolytic agent with the molecular formula C10H11NO4S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 0NOY894QRB, chemically known as glycine, n-(1-oxo-2-((2-thienylcarbonyl)thio)propyl)- but more generally known as stepronin, which bears US NIH Compound Identifier 54120. European Medicines Agency schedules Stepronin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10645MIG. The term STEPRONIN is an International Non-Proprietary Name.

UNSPSC 51162739 Stepronin, a Commodity code, covers pharmaceutical and medical products supplied to state and local agencies, with recent procurement activity focused on parenteral solutions, intravenous products, and opioid-response medications. State and local governments are buying specialized healthcare products including total parenteral nutrition (TPN) and peripheral parenteral nutrition (PPN) solutions, intravenous fluids, naloxone, and drug deactivation systems for delivery to correctional facilities, public health departments, and community health programs. The issuing bodies soliciting under this code include state corrections departments and county health authorities, reflecting the code's application across both custody and community health environments.

Recent opportunities span Washington State and Florida. The Washington State Department of Corrections posted RFQQK13020 on September 8, 2026, requesting quotes for parenteral products, services, and equipment with a due date of October 7, 2026, supporting eight correctional facilities across three regions (West, Central, and East) with strict delivery requirements—PN bags within 24 hours of order and other parenteral products within 8 hours. The solicitation encourages participation from small businesses (25%), minority-owned businesses (10%), women-owned businesses (6%), and veteran-owned businesses (5%), with DOC retaining the right to award up to three bidders per region. Seminole County, Florida issued IFB60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually for quarterly delivery to the Seminole County Community Health Building, with a response deadline of July 26, 2026. The Washington procurement emphasizes cold-chain logistics and clinical precision; the Florida procurement emphasizes public health supply volume. Both contracts run multiple years with fixed pricing requirements and standard insurance and compliance obligations.